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Abstract  
Introduction: Kaposi's sarcoma (KS) is a kind of cancer that causes flat or raised lesions containing Human herpes virus 8 (HHV8). The KS lesions 
are common among immunosuppressed HIV patients. Highly Active Antiretroviral (HHART) treats and prevents the development of KS. The objective 
of this study was to determine the presence of K1 and K15 (predominant alleles) genes in Kaposi's sarcoma-associated herpes virus (KSHV) among 
immunosuppressed patients due to HIV-1. Methods: this was a cross-sectional descriptive study where consecutive sampling technique was adopted 
to pick archived tissue blocks from the Thematic Unit of Anatomic Pathology, Department of Human Pathology, College of Health Sciences, University 
of Nairobi and Department of Laboratory Medicine, Histology Section, Kenyatta National Hospital. Results: upon staining 81 tissue blocks with H & E, 
84% (68/81) were diagnosed as KS and 16% (13/81) as KS-like. The K1 and K15 (P) genes were both detected at 88.9% (72/81) in the tissue 
blocks, with 95.8% (69/72) detection from KS and 4.2% (3/72) from the KS-like. Conclusion: the K1 and K15 (P) genes of KSHV were present 
among the immunosuppressed patients with Human Immunodeficiency Virus (HIV)-1. It is important to carry out K1 and K15 (P) genes detection on 
tissues that are diagnosed as KS or KS-like by histology technique. 
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Current studies indicate that all types of Kaposi's sarcoma (KS) are 
caused by Human Herpes Virus (HHV)-8 infections, and the difference 
in them is attributed by the contributions of many cofactors [1]. 
Genetic or environmental factors are essential for progression of KS 
resulting to heterogeneous circulation of the virus in different 
populations [2]. Immunosuppression due to Human 
Immunodeficiency Virus (HIV)-1 can result in the manifestation of 
Kaposi's sarcoma tumors [3]. The genome of HHV-8 is about 140.5 
Kilo base pair, and encompasses several terminal repeats [4]. The 
naming of HHV-8 genes is based on the genomic location, and the 
letter 'K' is deduced from Kaposi's sarcoma human virus (KSHV) [5]. 
The HHV-8 genes have been observed to play a role in the KS 
pathogenesis. K1 gene stimulates and augments other cells in a 
paracrine manner. Manifestation of KS is heightened when K1 gene 
which encodes for inflammation unites with the HIV-1 Tat protein [6]. 
K15 gene is located at the right end of HHV-8 genome and occurs in 
two alleles as P (Predominant) and M (minor). It has been shown to 
contribute to the angiogenic properties of the KSHV [7]. Viral 
pathogenesis of HHV-8 associated KS has been attributed to the 
interactions between host immune responses, K1 and K15 genes. In 
addition, K1 and K15 genes have also been detected in cells during 
latency period and have been linked to viral neoplasia [8]. The 
geographical distribution of HHV-8 has been well defined. However, 
what remains a puzzle is the reason for its high prevalence in Africa 
and Middle East and a relatively lower prevalence in United States 
and Northern Europe [9]. Studies have suggested the possibility of 
HHV-8 being transmitted through oral-fecal route but this still yet to 
be established [10]. The precise mode of transmission of HHV-8 is 
still not known but, the virus has been successfully detected in semen 
and saliva [11]. It is not recommended to test children and adults on 
a routine basis, for this reason the serological status of HHV-8 in 
patients infected with HIV is frequently unknown [12]. Primary 
diagnosis of KS is achieved by describing the morphological 
characteristics of the tumor using Haematoxylin and Eosin (H & E) 
staining technique [13]. Histological examination has shown that KS 
is a complex lesion and the presentation is made up of patch stage, 
plaque stage and a nodular stage [14]. Molecular technique is the 
recommended diagnostic method for confirmation of KS [15] and it is 
on this basis that this study was designed to detect K1 and K15 (P) 
genes of Human herpes virus-8 associated Kaposi's sarcoma among 
HIV-1 and Acquired Immunodeficiency Disease Syndrome (AIDS) 
patients using nested polymerase chain reaction (PCR) technique. 
Hypothesis: the existence KSHV gene K1 and K15 (P) gene is 





This was a cross-sectional descriptive study where 104 formalin-fixed 
paraffin-embedded (FFPE) tissues blocks were retrieved from the 
Thematic Unit of Anatomic Pathology, Department of Human 
Pathology, College of Health Sciences, University of Nairobi and 
Department of Laboratory Medicine, Histology Section, Kenyatta 
National Hospital between the year 2013 and 2016. The 
demographics, HIV-1 status, CD4 cell count, tumor location, number 
of tumors, and antiretroviral treatment status of the patients whose 
tissue blocks had been collected and used were obtained from the 
registry records in the cytology and human pathology department. 
For this study, the inclusion criteria were tissue blocks that were 
previously diagnosed as KS or KS-like with a comprehensive bio-data 
information linking the blocks and registry records. Tissue blocks 
previously diagnosed as KS or KS-like that had missing or incomplete 
bio-data information from the registry records were excluded from 
the study. Consecutive sampling technique was used to pick a total 
of 81 tissue blocks from the 104 FFPE because they had met the 
inclusion criteria. A rotary microtome was used to section FFPE blocks. 
  
Tissue sectioning: different blades per FFPE block were used to 
prevent carry-over of DNA. After each section, the surface of the 
microtome was sterilized using DNAZapTM PCR DNA (Thermo Fisher 
Scientific Company Cat No./ID: AM9890) degradation solutions. One 
tissue section was cut up to 10 µm thick. The tissue sections were 
processed for Hematoxylin and Eosin (H and E) staining and the 
results reported by a qualified human pathologist. 
  
DNA extraction: DNA extraction was carried out from the sectioned 
tissues using Qiagen kit GeneRead DNA FFPE (Qiagen®company Cat 
No./ID: 180134).The extraction kit removes paraffin and reverses 
formalin cross-links from the DNA tissues before it is bound to the 
QIAampMinElute column. The eluted DNA was then ready to be used 
for nested PCR. 
  
DNA detection: taq PCR Core Kit-Qiagen (Qiagen® company Cat 
No./ID: 201223) was used to detect K1 and K5 (P) gene. The two (K1 
& K15 (P)) selected genes of KSHV were detected using two set of 
primers. The set of primers used were; K1 product size 868 bpK1a-f 
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ATGTTCCTGTATGTTGTCTGC; K1a-r AGTACCAATCCACTGGTTGCG K1 
product size 840 bp K1b-f GTCTGCAGTCTGGCGGTTTGC; K1b-r 
CTGGTTGCGTATAGTCTTCCG, K15 (P) product size  
365 bp K15P-OF TGCAGGCTTGGTCATGGGTTAC; K15P-OR 
GGGACCACGCTGCAATTAAATG; K15 (P) product size 285 bpK15-3C 
ACGCATACATGTACTGCCAC; K15-4C CTTTGATATTGCCAGTGGTG. 
The PCR cycling condition of all the two targeted KS regions were 
similar and it consisted of 30 number of cycles which entailed; initial 
denaturation at 94°C for 3 minutes, denaturation at 94°C for 1 
minute, annealing at 63°C for 1 minute, extension at 72°C for 1 
minute and final extension at 72°C for 10 minutes. The amplified PCR 
products were analyzed by electrophoresis on a 1% agarose gel 
containing ethidiumbromide (1µl/ml of agarose solution) and were 
visualized under ultraviolet light alongside 1Kb DNA ladder. A known 
case of KS was used as positive control and RNase free water used 
as a negative control. 
  
Ethical clearance: authors of this manuscript obtained ethical 
clearance for the study from Kenyatta National Hospital and University 
of Nairobi (ethical clearance number: P682/11/2014). 
  
Statistical analysis: sample size of 81 tissue blocks was calculated 




where Z^2 = 1.96, p = 5.6% based on prevalence HIV infection, 
trends, and risk factors among persons aged 15-64 years in Kenya: 
results from a nationally representative study [17], q = 0.944, d^2 = 
0.05^2, n = 1.962 X ((0.056) X (1-0.056))/(0.05)^2 = 81. The data 
was analyzed using SPSS version 21 where the relationship between 
K1, K15 (P) genes and clinicopathologic factors were tested by chi-
square, multiple logistic analysis and t-test. A P value < 0.05 was 





The K1 and K15 (P) genes detected as positive were 88.9% (72/81) 
and negative was 11.1% (9/81). Among the 88.9% tissue bocks that 
were positive for the targeted HHV-8 genes, 41.7% (30/72) were 
from female and 58.3% (30/72) male. All the subjects whose tissue 
blocks were retrieved for this study were found to be HIV positive. 
The antiretroviral status of the subjects was also determined, and it 
showed that out of the 88.9% that had K1 and K15 (P) genes 
detected, 95.8% (69/72) were on antiretroviral treatment and 4.2 
(3/72) were HAART naïve. The CD4 counts of the subjects whose 
tissue blocks were retrieved from the records demonstrated that none 
of the recruited subjects had a CD4 count of above 350 cell/ mm3. The 
number of CD4 count was grouped into two groups, 250 being the 
cut-off point. Among the tissue blocks that had the K1 and K15 (P) 
genes detected 51.4% (37/72) had CD4 count above 250 cells/ 
mm3 and 48.6% (35/72) had CD4 count below 250 cells/ mm3. The 
distribution of age and CD4 cell count were significantly skewed and 
were bimodal among those who had the K1 and K15 (P) genes 
detected at a P value of 0.039 and 0.004 respectively (Shapiro test of 
normality). The records also indicated the distribution and the number 
of KS lesions among these subjects whose tissue samples were 
archived as FFPE blocks. The number of KS lesions in these subjects 
was grouped into two, above 10 and below 10. The tissue blocks that 
the K1 and K15 (P) genes were detected and had > 10 KS lesions was 
55.6% (40/72) and < 10 KS lesion 44.4% (32/72). The distribution 
of KS was grouped as either localized or generalized, with 37.5% 
(27/72) localized and 62.5 (45/72) generalized among those that the 
K1 and K15 (P) genes were detected. The distribution of the KS 
lesions among the tissue blocks that had the two targeted genes 
detected were as follows: skin 31.6% (23/72), lower limbs 27.8% 
(20/72), lymphedema 16.7% (12/72), upper limbs 13.9% (10/72), 
palate 5.6% (4/72), trunk 1.4% (1/72), genitals 1.4% (1/72) and eye 
1.4% (1/72). The study did histology screening on the retrieved tissue 
blocks to describe the morphology of the KS lesions. Tissue blocks 
were processed, sectioned, stained by H & E, results read by qualified 
pathologist and were described as patches, plaques and/or nodules 
(Figure 1). In this study, among the tissue blocks that had K1 and 
K15 (P) gene detected, histology results showed that 22.2% (16/72) 
were plaques, 8.3% (6/72) patches and 69.4% (50/72) nodules. The 
tissue blocks that were diagnosed as KS-like were 16% (13/81) out 
of which 4.2% (3/72) had the two target genes detected. Multiple 
logistic regression analysis (Table 1) was done to determine the 
prevalence odds ratio and this model was found to be significant at P 





Genotyping analysis in this study revealed that the Kaposi's sarcoma-
associated herpes virus (KSHV) genes, K1 and K15 (P) were detected 
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among the selected tissue blocks. These findings affirm the earlier 
hypothesis that K1 and K15 (P) genes of Kaposi's sarcoma-associated 
herpes virus (KSHV) were present in the tissue blocks retrieved from 
patients with HIV-1 and AIDS. A previous study [18] conducted at the 
same facility looked at the prevalence of KS and it was noted that the 
existence was ranging from 2-5%. The discrepancy could be 
attributed to the number of cases as the previous study had total of 
1108 cases of KS consisting of 911 males and 197 females. It is worth 
noting that unlike the former study that used clinical and histological 
diagnosis, the current study adopted the use of a more sensitive test 
that detected HHV-8 Deoxyribonucleic acid (DNA). In Morocco, an 
epidemiology study on Kaposi's sarcoma showed that they 
successfully detected the K1 gene at 870 bp in 35/35 DNA samples 
and K15 (P) was spotted in 31/35 using 362 bp PCR product [19]. In 
Zambia, the K1 sequences were detected in blood from HIV positive 
febrile infants who had KS. The study went further and did a distinct 
grouping of KS strains and it was noted that K1 glycoprotein was 
highly variable [20]. A study on the evolution of K15 gene and HHV-
8 recombination was done in Uganda and the findings indicated that 
K15 was highly divergent with P allele being predominant in 30/30 KS 
patients. The whole K15 gene (2101 bp) was used in the analysis to 
establish the existence of HHV-8 [21]. In Zimbabwe, the existence of 
K1 diversity was evaluated and it was observed that there was no 
significant relationship that was found to exist amongst K1 subtypes 
and the clinico-demographic features among the 65 AIDS-KS patients 
[22]. The results of this study will add to the literature on the existing 
list of countries that have successfully detected K1 and K15 (P) genes 
associated with AIDS-KS in Africa. The crude prevalence odds ratio 
(POR) from Table 1 indicated that none of the variables were found 
significant (P < 0.05); but some variables like gender, CD4 cell count, 
treatment and distribution of KS lesions showed a strength in the 
association: gender for example, we noticed that compared to 
females, males were twice represented among those with K1 and K5 
(P) genes cases. 
  
These findings were in agreement with another study [23] where it 
was observed that in Africa, tumors associated with KS were likely to 
be diagnosed in male patients. From the registry records where the 
bio-data and clinical information of the patients, whose tissue blocks 
were used in this study, none had a CD4 count above 350 cell/ mm3. 
Other studies [24, 25] have also indicated that CD4 cell count <350 
cells/ mm3 are linked to high risk of developing KS whether one is on 
HIV treatment or not. However, recommendations have been made 
on the need to lookout on KS cases in subjects with high CD4 cell 
count [24]. For treatment, HAART naive group in this study were 
found to be twice represented among the K1 and K5 (P) genes cases 
compared to those on treatment. Typically, when a patient with AIDS 
associated KS adheres to antiretroviral therapy (ART), their CD4 cell 
count is elevated and clinical presentation of KS tumors either stabilize 
or resolve [26]. However, when a patient is on ganciclovir (an antiviral 
used in the treatment of various forms of herpes) the replication of 
KSHV is inhibited [27], although after the manifestation of KS tumors 
these drugs may not be of use. Confirmed AIDS-KS patients should 
be on highly active antiretroviral therapy (HAART) to achieve 60-90% 
remission [28]. The most likely reason why subjects in this study had 
KS presentations despite being on ART could be non-adherence or 
antiretroviral resistance. Kaposi's sarcoma tumors resulting from HIV 
and AIDS are known to be severe, resistant and are caused by HHV-
8 [29]. Typical KS lesions include macules, papules and nodules. 
However other morphological variants that have been used to 
describe it are: patches, plaques, exophytic, infiltrative, keloidal, 
telangiectatic, cavernous, ulcerative, bullous and verrucous types 
[30]. For this study, the histological morphology of the KS lesions was 
nodular, plaques and patches. Majority of the morphological cases 
were nodular. The distribution of KS in terms of histological 
morphology was consistent with similar studies that were conducted 
in Tanzania [31] and Zambia [32] where it was observed that nodular 
had the most distribution at 68.7%, (82/120) and 60.7% (51/84) 
respectively. In this study, among those who presented with nodular 
morphology of KS 61.2% (30) were males and 38.8% (19) females. 
These findings were consistent with a study conducted in Uganda [33] 
where women were less likely to have nodular lesions of KS compared 
to men. In the Uganda study, reduced rate of KS among females 
might have been due to gender related factors that include hormonal, 





In conclusion, Kaposi's sarcoma-associated herpes virus (KSHV) 
genes, K1 and K15 (P) were detected among tissue blocks collected 
from patients infected with HIV-1 and AIDs. The morphology of KS 
lesions upon histological diagnosis was distributed as patches, 
plaques and nodules. East Africa is traditionally known to have a high 
prevalence of KS [34]. The precision of pathological diagnosis of KSHV 
should incorporate skin punch biopsy and HHV-8 LANA-1 (Latency- 
associated nuclear antigen-1). 
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What is known about this topic 
 In resources limited health facilities, Kaposi's sarcoma is 
routinely diagnosed by clinical presentations and cytological 
identification using H & E staining technique. 
What this study adds 
 There is need to detect HHV-8 using a robust diagnostic 
techniques to aid a precise patient management because 
the patients in this study had a dark skin pigmentation and 
in another study conducted on dark-skinned patients, KS 
had been confirmed to mimic a number of non-KS like 
dermatological conditions; 
 It further stated that the patients who presented with 
violaceous skin lesions were likely to be considered a 











Rodgers Norman Demba, Sylviah Mweyeli Aradi, Nathan Shaviya and 
Walter Mwanda: critical revision of the manuscript for important 
intellectual content; Rodgers Norman Demba, Sylviah Mweyeli Aradi 
and Walter Mwanda: drafting of the manuscript; Rodgers Norman 
Demba and Walter Mwanda: analysis or interpretation of data. 
Rodgers Norman Demba, Sylviah Mweyeli Aradi: acquisition of the 
data. Rodgers Norman Demba and Walter Mwanda: conception or 






Authors of this manuscript would like to extend their gratitude to 
Kenyatta National Hospital and University of Nairobi for allowing them 
to use their archived tissue blocks. 
  
  
Table and figure  
 
Table 1: estimated of crude prevalence odds ratio (POR) using simple 
logistic regression for K1 and K15 (P) genes  
Figure 1: microscopic identification of Kaposi's sarcoma (KS) and KS-
like using H and E staining, X 20; (A) patch: patch stage Kaposi 
sarcoma showing vessels protruding into a larger vascular space 
characteristic of the promontory sign; (B) nodular: fascicles of 
relatively monomorphic spindled cells, with slit-like vascular channels 
containing erythrocytes; (C) plaque: plaque stage KS with bizarre 
vessels; there is erythrocyte extravasation and hemosiderin 
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Table 1: estimated of crude prevalence odds ratio (POR) using simple logistic regression for K1 and K15 (P) genes  
Characteristics n (%) 
K1 & K15 (P) gene 
positive n (%) 
POR 95% CI P value 
Gender     0.57 0.14 - 2.31 0.428 
Male 46(56.8) 42(58.3)       
Female 35(43.2) 30(41.7)       
Age     1.07 0.99 – 1.18 0.104 
18-29yrs 9(11.1) 7(9.7)       
30-39yrs 39(48.1) 34(47.2)       
40-49yrs 23(28.4) 21(29.2)       
50-59yrs 6(7.4) 6(8.3       
60 yrs & above 4(4.9) 4(5.6)       
On treatment     0.35 0.03- 3.75 0.377 
On ARVs 77(95.1) 69(95.8)       
HAART naive 4(4.9) 3(4.2)       
Number of lesion     1.0 0.25- 4.03 1.014 
>10 44(54.3) 39(54.2)       
<10 37(45.7) 33(45.8)       
Distribution of lesion     0.21 0.03- 1.76 0.152 
Generalized 53(65.4) 45(62.5)       
Localized 28(34.6) 27(37.5)       







Figure 1: microscopic identification of Kaposi's sarcoma (KS) and KS-like using H and E staining, X 20; (A) patch: 
patch stage Kaposi sarcoma showing vessels protruding into a larger vascular space characteristic of the 
promontory sign; (B) nodular: fascicles of relatively monomorphic spindled cells, with slit-like vascular channels 
containing erythrocytes; (C) plaque: plaque stage KS with bizarre vessels; there is erythrocyte extravasation and 
hemosiderin pigmentation; (D) KS-like: morphological feature suggestive of KS 
 
